Mark Delaney: Juniper, hey — did you see the thing that dropped this week? Because I've been kind of stewing on it since yesterday.
Juniper Vale: The FDA thing? Yeah, I read it twice because I thought I'd missed something.
Mark Delaney: Here it is — the FDA Pharmacy Compounding Advisory Committee, the PCAC, they've got a meeting scheduled July 23rd and 24th, White Oak Campus in Silver Spring, and they're voting on whether seven peptides can be mass-produced by compounding pharmacies. Seven. And the FDA's own staff scientists already looked at the evidence and said — uh, there's little to no support for the safety or efficacy of any of them in humans. And the vote is still happening.
Juniper Vale: Right — the agency's own scientists said the human evidence basically isn't there, and we're still having the vote.
Mark Delaney: And then — and this is the jaw-drop part for me — Robert F. Kennedy Jr., the Health Secretary, publicly called himself a "big fan" of these peptides. The ones his own scientists are pumping the brakes on.
Juniper Vale: A "big fan." That's not regulatory language, that's an endorsement. From the person who runs the department whose scientists are saying wait, hold on.
Mark Delaney: BPC-157, TB-500 — those are the two you hear about the most, the wound healing, the recovery stuff — most of what we've got on them is animal data. Rats and mice, not people. So what we're actually trying to figure out is: how did we get to a place where a vote like this is even on the table?
Juniper Vale: Think of compounding pharmacies like a tailor for medicine — they take an existing approved drug and fit it to one patient. Different dose, allergen-free version, something you can swallow instead of inject. That's the whole job. What this PCAC vote is deciding is whether that same tailor shop can now manufacture entirely new clothes from scratch, at factory scale, for anyone who wants them.
Mark Delaney: Wait — so the original rule wasn't designed to cover this at all?
Juniper Vale: No. To compound a drug from scratch, the ingredient has to appear on the FDA's bulk drug substances list — that's the gate. The PCAC vote is literally deciding whether these seven peptides qualify for that list. That's the mechanism. It's not a formality.
Mark Delaney: And the reason this matters right now is — uh, okay, the market's already live. Like, you can order semax or epitalon online this week. You get a vial in the mail, it says 'for research use only,' and you just... inject it yourself. No pharmacy license behind it, no safety review. The 'research use only' label is basically the loophole that makes all of that legal-ish.
Juniper Vale: And that's actually the part that matters — a yes vote doesn't create that market. Fortune already flagged this could be telehealth's next multibillion-dollar market because the demand is already there. The vote just decides whether a pharmacy license gets attached to the transaction.
Mark Delaney: Right — but the part that doesn't fit is the person who has no recourse right now. If something goes wrong with that vial they injected, there's nothing behind it. No regulated chain.
Juniper Vale: Which is why — and we're going to get into this — the framing that this is a close scientific call doesn't actually hold. The FDA staff scientists were not ambiguous. That part gets messier.
Mark Delaney: That framing going around — that this is a legitimate scientific debate with two reasonable sides — I don't buy it. Because the FDA staff scientists didn't write a hedged, 'well, it's complicated' memo. They said little to no evidence. For all seven peptides. That's not a close call dressed up as one.
Juniper Vale: And people will say — okay, but anecdote exists. Someone takes BPC-157 and their knee heals faster. MOTS-c and they feel sharper. That's real to that person.
Mark Delaney: Right — but that's not the same thing as clinical evidence, and I think that's the slip.
Juniper Vale: No, it's not. One person's story is valuable, a thousand people's stories are still not a clinical trial. The absence of human trial data isn't bureaucratic caution — that's the whole point of the evidence bar. It exists because animal studies miss things. Drug interactions, organ toxicity, rare adverse events — those don't always translate from a rat. And then Kennedy is out there calling himself a 'big fan,' which — I mean, that's the Health Secretary publicly endorsing compounds his own agency's scientists just rejected. That's not a disagreement at the margins, that's pressure on the process itself.
Mark Delaney: And Dr. Céline Gounder — she published a piece on July 14th and called it 'Big Pharma with the guardrails off.' Wide consumer access to unevaluated compounds, no clinical proof, but all the risk. That framing kind of cuts through the noise for me.
Juniper Vale: And the twist is — the PCAC vote isn't even binding. The FDA can ignore the panel entirely, yes or no, either direction. Which makes the political pressure from Kennedy way more legible. If the science already said no, and the vote's non-binding anyway, what's actually being decided here isn't really scientific.
Mark Delaney: And that's the thing that keeps nagging at me — if this vote goes yes, and two years from now people start reporting side effects that never showed up in the animal studies, uh... where does that actually land? Like who eats that?
Juniper Vale: The consumer. Right now, with no safety infrastructure behind them — no regulated chain, no liability trail. And once these peptides are on the bulk drug substances list, the commercial pressure to keep them there is going to be enormous. Fortune's already calling it telehealth's next multibillion-dollar market. You don't walk that back easily.
Mark Delaney: So the structural question is just... sitting there. Should the pathway that was designed for drug shortages become the default route for novel unapproved medicine. And I don't — I genuinely don't know the answer to that.
Juniper Vale: Neither do I. And I think that's where we have to leave it.
